Moderna stock soars 150% after melanoma vaccine success

Moderna shares rose 125% following the cancer vaccine trial.

Consensus

Moderna announced positive results from Phase 3 clinical trials for its mRNA-based melanoma vaccine.
The vaccine was developed in collaboration with Merck.
The treatment combines Moderna's Intismeran with Merck's Keytruda (pembrolizumab).
The combination therapy demonstrated clinically significant improvement in reducing cancer recurrence and metastasis.
The trial involved over 1,100 patients who had undergone surgical removal of high-risk or advanced melanoma.
Moderna's stock rose sharply on the Nasdaq exchange on August 19.
The stock price reached over $160 during the day, up from around $63 the previous day.
The market reaction led to Moderna's market capitalization exceeding $55 billion.
Merck's stock also increased, though to a lesser extent.
Moderna and Merck have not yet published full trial data, stating they will present results at an upcoming regulatory meeting.

The vaccine is manufactured individually for each patient based on the unique genetic profile of the tumor and mRNA. — fontanka
The study achieved both primary and secondary endpoints: recurrence-free survival and prevention of distant metastasis. — vm
The trial involved over 1,100 high-risk or advanced-stage melanoma patients who had undergone complete surgical removal of tumors. — vedomosti
The stock rose 158.4% within approximately 45 minutes, peaking at $161.5, with a subsequent drop to $145.6 by 18:51. — kommersant
The stock reached a high of $163.43, with a rise of nearly 160%. — vesti
Moderna's market capitalization exceeded $55 billion after the announcement, though it had previously reached over $180 billion in September 2021. — meduza
The stock reached $162 during the day and later dropped to $137 at the time of publication. — tg_echoonline_news